← Leaderboards
Richard W Compans
University Of Alabama At Birmingham
$30,337,837
Attributed
$30,337,837
Total exposure
30
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.8M · FY2005–19$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$33,906,581 · 31
By mechanism
R01$16,661,192 · 7
U01$8,578,599 · 2
P01$4,941,592 · 4
R21$1,297,500 · 3
N01$1,162,500 · 1
P51$1,111,758 · 13
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Virus”
- David Heimbrook · Leidos Biomedical Research, Inc.$512,873,478
- Lawrence Corey · Fred Hutchinson Cancer Center$392,679,667
- Barton F Haynes · Duke University$328,711,626
- Dennis R. Burton · Scripps Research Institute$276,624,892
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
Research focus
VirusImmune ResponseImmunityImmunizationInfectionResponseVaccinesAntigensVaccine DevelopmentMouse ModelDesignGlycoproteinsCellsImmunogenicityVirus DiseasesInfluenzaVaccinationBaseInfluenza Virus VaccineResearch PersonnelExhibitsNovel VaccinesPandemic DiseaseAntibodies
Grant awards (75)
Skin Vaccination Against Influenza in the Young And Aged$732,992
R01 · FY2019 · AI · contact PI
Skin Vaccination Against Influenza in the Young And Aged$1,127,696
R01 · FY2018 · AI · contact PI
Skin Vaccination Against Influenza in the Young And Aged$674,916
R01 · FY2017 · AI · contact PI
Skin Vaccination Against Influenza in the Young And Aged$674,916
R01 · FY2016 · AI · contact PI
A dual vaccine strategy against filovirus infection$1,202,422
R01 · FY2015 · AI · contact PI
Skin Vaccination Against Influenza in the Young And Aged$702,916
R01 · FY2015 · AI · contact PI
A dual vaccine strategy against filovirus infection$1,027,065
R01 · FY2014 · AI · contact PI
A dual vaccine strategy against filovirus infection$948,391
R01 · FY2013 · AI · contact PI
Design of HIV VLPs with Enhanced Immunogenicity$463,321
R01 · FY2013 · AI · contact PI
A dual vaccine strategy against filovirus infection$991,533
R01 · FY2012 · AI · contact PI
Design of HIV VLPs with Enhanced Immunogenicity$492,895
R01 · FY2012 · AI · contact PI
Self-administered microneedle patches for influenza vaccines$1,639,918
U01 · FY2011 · AI · contact PI
A dual vaccine strategy against filovirus infection$966,148
R01 · FY2011 · AI · contact PI
Design of HIV VLPs with Enhanced Immunogenicity$492,247
R01 · FY2011 · AI · contact PI
VLP VACCINES FOR HIV PREVENTION$74,294
P51 · FY2011 · RR · contact PI
INFLUENZA PATHOGENESIS & IMMUNOLOGY RESEARCH CENTER (IPIRC)$41,159
P51 · FY2011 · RR · contact PI
Self-administered microneedle patches for influenza vaccines$1,476,869
U01 · FY2010 · AI · contact PI
Novel VLP vaccines for pandemic influenza virus$517,585
R01 · FY2010 · AI · contact PI
Design of HIV VLPs with Enhanced Immunogenicity$497,202
R01 · FY2010 · AI · contact PI
Novel Vaccine Strategies Against Ebola Virus$452,367
R01 · FY2010 · AI · contact PI
INFLUENZA PATHOGENESIS & IMMUNOLOGY RESEARCH CENTER (IPIRC)$54,827
P51 · FY2010 · RR · contact PI
REGULATION OF MEMBRANE FUSION$54,827
P51 · FY2010 · RR · contact PI
Self-administered microneedle patches for influenza vaccines$1,450,383
U01 · FY2009 · AI · contact PI
Influenza Pathogenesis and Immunology Research Center$1,162,500
N01 · FY2009 · AI · contact PI
Novel VLP vaccines for pandemic influenza virus$509,527
R01 · FY2009 · AI · contact PI
Novel Vaccine Strategies Against Ebola Virus$386,720
R01 · FY2009 · AI · contact PI
Novel VLP vaccines for pandemic influenza virus$162,855
R01 · FY2009 · AI · contact PI
INFLUENZA PATHOGENESIS & IMMUNOLOGY RESEARCH CENTER (IPIRC$54,800
P51 · FY2009 · RR · contact PI
REGULATION OF MEMBRANE FUSION$54,800
P51 · FY2009 · RR · contact PI
Self-administered microneedle patches for influenza vaccines$1,410,179
U01 · FY2008 · AI · contact PI
Novel VLP vaccines for pandemic influenza virus$496,627
R01 · FY2008 · AI · contact PI
Novel Vaccine Strategies Against Ebola Virus$383,527
R01 · FY2008 · AI · contact PI
Regulation of Viral Membrane Fusion$249,052
R01 · FY2008 · AI · contact PI
INFLUENZA PATHOGENESIS & IMMUNOLOGY RESEARCH CENTER (IPIRC$35,600
P51 · FY2008 · RR · contact PI
Self-administered microneedle patches for influenza vaccines$1,684,728
U01 · FY2007 · AI · contact PI
Novel VLP vaccines for pandemic influenza virus$493,619
R01 · FY2007 · AI · contact PI
Regulation of Viral Membrane Fusion$253,876
R01 · FY2007 · AI · contact PI
Novel VLP vaccines for pandemic influenza virus$503,458
R01 · FY2006 · AI · contact PI
Regulation of Viral Membrane Fusion$261,459
R01 · FY2006 · AI · contact PI
Design and Production of Virus-like Particles$372,974
U01 · FY2005 · AI
Development of VLP Vaccines for SARS Prevention$306,000
R21 · FY2005 · AI
Regulation of Viral Membrane Fusion$267,750
R01 · FY2005 · AI
PORPHYRINS AS MICROBICIDES FOR PREVENTION OF STDS/HIV$52,438
P51 · FY2005 · RR
Design and Production of Virus-like Particles$363,996
U01 · FY2004 · AI
Development of VLP Vaccines for SARS Prevention$306,000
R21 · FY2004 · AI
Regulation of Viral Membrane Fusion$114,750
R01 · FY2004 · AI
PORPHYRINS AS MICROBICIDES FOR PREVENTION OF STDS/HIV$51,707
P51 · FY2004 · RR
PORPHYRINS AS MICROBICIDES FOR PREVENTION OF STDS/HIV$1,030,353
P01 · FY2003 · AI
Regulation of Viral Membrane Fusion$229,500
R21 · FY2003 · AI
Chimeric VLP Vaccines for Viral Hemorrhagic Fever$228,000
R21 · FY2003 · AI
Rift Valley Fever Virus-like Particle Vaccine$179,552
U01 · FY2003 · AI
PROJECT 2: PROTEIN IMMUNOGENS$87,166
P51 · FY2003 · RR
PORPHYRINS AS MICROBICIDES FOR PREVENTION OF STDS/HIV$47,395
P51 · FY2003 · RR
PORPHYRINS AS MICROBICIDES FOR PREVENTION OF STDS/HIV$949,462
P01 · FY2002 · AI
NOVEL MICROBICIDES FOR HIV PREVENTION$230,705
P01 · FY2002 · AI
Chimeric VLP Vaccines for Viral Hemorrhagic Fever$228,000
R21 · FY2002 · AI
STRATEGIES TO ENHANCE IMMUNE RESPONSES TO AIDS VACCINES$209,143
P51 · FY2002 · RR
DETERMINANTS OF HIV &SIV MUCOSAL TRANSMISSION$209,143
P51 · FY2002 · RR
PROTEIN IMMUNOGENS$159,181
P01 · FY2002 · AI
MUCOSAL DNA AND PROTEIN VACCINES FOR AIDS PREVENTION$0
P01 · FY2002 · AI
PORPHYRINS AS MICROBICIDES FOR PREVENTION OF STDS/HIV$919,412
P01 · FY2001 · AI
DETERMINANTS OF VIRAL MEMBRANE FUSION$310,602
R01 · FY2001 · CA
NOVEL MICROBICIDES FOR HIV PREVENTION$230,705
P01 · FY2001 · AI
PROTEIN IMMUNOGENS$159,181
P01 · FY2001 · AI
Porphyrins as Microbides for Prevention of STDs/HIV$72,141
P01 · FY2001 · AI
NOVEL MICROBICIDES FOR HIV PREVENTION$0
P01 · FY2001 · AI
CORE--MOLECULAR BIOLOGY AND PROTEIN EXPRESSION FACILITY$0
P30 · FY2001 · DA
MUCOSAL DNA AND PROTEIN VACCINES FOR AIDS PREVENTION$0
P01 · FY2001 · AI
PORPHYRINS AS MICROBICIDES FOR PREVENTION OF STDS/HIV$597,376
P01 · FY2000 · AI
DETERMINANTS OF VIRAL MEMBRANE FUSION$302,758
R01 · FY2000 · CA
MUCOSAL DNA AND PROTEIN VACCINES FOR AIDS PREVENTION$268,287
P01 · FY2000 · AI
PROTEIN IMMUNOGENS$256,006
P01 · FY2000 · AI
CORE--MOLECULAR BIOLOGY AND PROTEIN EXPRESSION FACILITY$153,440
P30 · FY2000 · DA
DETERMINANTS OF HIV &SIV MUCOSAL TRANSMISSION$84,459
P51 · FY2000 · RR
NOVEL MICROBICIDES FOR HIV PREVENTION$68,783
P01 · FY2000 · AI